{"product_id":"scripps-39th-annual-new-treatments-in-chronic-liver-disease-2025","title":"Scripps 39th Annual New Treatments in Chronic Liver Disease 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hepatologists, gastroenterologists, internists, transplant specialists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e39TH ANNUAL New Treatments in Chronic Liver Disease\u003c\/p\u003e\n\u003cp\u003eEducational Objectives\u003c\/p\u003e\n\u003ch3\u003eAfter attending this live activity, participants should be able to:\u003c\/h3\u003e\n\u003cp\u003eCite new strategies for identifying and managing metabolic liver disease.\u003c\/p\u003e\n\u003cp\u003eDiscuss potential new treatments for alcohol related liver disease.\u003c\/p\u003e\n\u003cp\u003eSummarize novel markers and therapies in PBC and PSC.\u003c\/p\u003e\n\u003cp\u003eEvaluate liver masses and new therapeutic options for HCC.\u003c\/p\u003e\n\u003cp\u003eEmploy strategies for treating and managing ascites and hepatorenal syndrome.\u003c\/p\u003e\n\u003cp\u003eThe Scripps 39th Annual New Treatments in Chronic Liver Disease Conference (2025) is best for hepatologists, gastroenterologists, internists, transplant specialists, and allied health professionals who want CME‑accredited updates on the latest therapies, diagnostics, and management strategies for chronic liver disease.\u003c\/p\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003cp\u003eHepatologists and gastroenterologists managing patients with cirrhosis, hepatitis, NAFLD\/NASH, and other chronic liver conditions.\u003c\/p\u003e\n\u003cp\u003eTransplant hepatologists and surgeons involved in liver transplantation and advanced liver failure care.\u003c\/p\u003e\n\u003cp\u003eInternal medicine and primary care physicians who need practical updates for managing liver disease in outpatient settings.\u003c\/p\u003e\n\u003cp\u003eResidents, fellows, and trainees preparing for board exams or subspecialty practice in hepatology or GI.\u003c\/p\u003e\n\u003cp\u003eNurses, nurse practitioners, and physician assistants working in hepatology, gastroenterology, or transplant programs.\u003c\/p\u003e\n\u003cp\u003eWhat You’ll Learn\u003c\/p\u003e\n\u003cp\u003eLatest pharmacologic therapies for viral hepatitis, autoimmune hepatitis, NAFLD\/NASH, and cholestatic liver diseases.\u003c\/p\u003e\n\u003cp\u003eAdvances in diagnostics: non‑invasive fibrosis assessment, imaging, and biomarkers.\u003c\/p\u003e\n\u003cp\u003eManagement of cirrhosis and portal hypertension including complications such as ascites, variceal bleeding, and hepatic encephalopathy.\u003c\/p\u003e\n\u003cp\u003eUpdates in liver transplantation: patient selection, immunosuppression, and outcomes.\u003c\/p\u003e\n\u003cp\u003eEmerging therapies and clinical trials shaping the future of chronic liver disease treatment.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSaturday, March 15, 2025\u003c\/p\u003e\n\u003cp\u003e7 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/p\u003e\n\u003cp\u003e8 a.m. Welcome \u0026amp; Introduction Identifying And Managing Metabolic Liver Disease\u003c\/p\u003e\n\u003cp\u003e8:15 a.m. Use of Surrogate Markers and Algorithms to Identify High Risk Patients and Optimize Outcomes\u003c\/p\u003e\n\u003cp\u003e8:45 a.m. Lifestyle Recommendations in Clinical Practice\u003c\/p\u003e\n\u003cp\u003e9:30 a.m. Incretins for Patients with MASH and T2D\u003c\/p\u003e\n\u003cp\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/p\u003e\n\u003cp\u003e10:30 a.m. Drug Development for MASH\u003c\/p\u003e\n\u003cp\u003e11:15 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eNoon Non-CME Lunch Symposium Hosted by Gilead Sciences Evolving Therapies For Advanced Liver Care\u003c\/p\u003e\n\u003cp\u003e1 p.m. CAMs for HBV: How Do They Work and How Should We Use Them?\u003c\/p\u003e\n\u003cp\u003e1:30 p.m. New Guidance for Hepatitis B and C\u003c\/p\u003e\n\u003cp\u003e2 p.m. All Things Itchy: PBC, PSC, and Pruritus\u003c\/p\u003e\n\u003cp\u003e2:30 p.m. Break \u0026amp; View Exhibits\u003c\/p\u003e\n\u003cp\u003e2:45 p.m. Alcohol Hepatitis\u003c\/p\u003e\n\u003cp\u003e3:15 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e3:45 p.m. Adjourn\u003c\/p\u003e\n\u003cp\u003e4 p.m. Welcome Reception\u003c\/p\u003e\n\u003cp\u003eSunday, March 16, 2025\u003c\/p\u003e\n\u003cp\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/p\u003e\n\u003cp\u003e7:55 a.m. Welcome \u0026amp; Announcements ESLD, HCC And Transplantation\u003c\/p\u003e\n\u003cp\u003e8 a.m. Refractory Hepatic Encephalopathy\u003c\/p\u003e\n\u003cp\u003e8:30 a.m. Mock HCC Tumor Board\u003c\/p\u003e\n\u003cp\u003e9:30 a.m. Systemic Therapies for HCC\u003c\/p\u003e\n\u003cp\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/p\u003e\n\u003cp\u003e10:30 a.m. WILLIAM S. HAUBRICH LECTURE: ASOs and siRNAs for HBV—How Do They Work and How Should We Use Them?\u003c\/p\u003e\n\u003cp\u003e11:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eNoon Final Adjournment\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405801705668,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Scripps-39th-Annual-New-Treatments-in-Chronic-Liver-Disease-2025.jpg?v=1784216387","url":"https:\/\/medicalcoursespro.com\/products\/scripps-39th-annual-new-treatments-in-chronic-liver-disease-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}